Merck KGaA launches Phase 3 push for lupus skin disease with enpatoran trials

The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations

Merck KGaA’s Belen Garijo to become CEO of Sanofi

Garijo will be the first woman to lead Sanofi in its history

Merck KGaA launches ChemiSphere App to digitize lab workflows

The ChemiSphere app exemplifies how M-Trust technology transforms workflows into seamless digital experiences

Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder

Merck KGaA fires up new supercomputer to turbocharge scientific breakthroughs

Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure

Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

Merck KGaA reports long-term OGSIVEO phase 3 data demonstrating sustained efficacy and safety in desmoid tumors

Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile

Merck KGaA to acquire chromatography business of JSR Life Sciences

Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions

Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

Merck KGaA bestows 2025 Future Insight Prize to Helmholtz Center’s Magdalena Gotz for breakthroughs in brain regeneration

Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich